Publication | Closed Access

FEC (5-fluorouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer. A multicentric randomised study. Final results

Advanced Breast CancerBreast OncologyMedicinePharmacologyBreast CancerPharmacotherapyFirst-line TreatmentVersus EmCancer TreatmentAnti-cancer AgentOncologyCancer Research